

Ana I Casas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11624003/publications.pdf>

Version: 2024-02-01

17
papers

1,397
citations

623734

14
h-index

888059

17
g-index

21
all docs

21
docs citations

21
times ranked

2132
citing authors

#	ARTICLE	IF	CITATIONS
1	Time-dependent dual effect of NLRP3 inflammasome in brain ischaemia. <i>British Journal of Pharmacology</i> , 2022, 179, 1395-1410.	5.4	19
2	Implication of type 4 NADPH oxidase (NOX4) in tauopathy. <i>Redox Biology</i> , 2022, 49, 102210.	9.0	12
3	Network pharmacology: curing causal mechanisms instead of treating symptoms. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 136-150.	8.7	294
4	Network medicine for disease module identification and drug repurposing with the NeDRex platform. <i>Nature Communications</i> , 2021, 12, 6848.	12.8	39
5	Isoform-selective NADPH oxidase inhibitor panel for pharmacological target validation. <i>Free Radical Biology and Medicine</i> , 2020, 148, 60-69.	2.9	50
6	On the Clinical Pharmacology of Reactive Oxygen Species. <i>Pharmacological Reviews</i> , 2020, 72, 801-828.	16.0	70
7	Early toll-like receptor 4 blockade reduces ROS and inflammation triggered by microglial pro-inflammatory phenotype in rodent and human brain ischaemia models. <i>British Journal of Pharmacology</i> , 2019, 176, 2764-2779.	5.4	44
8	From single drug targets to synergistic network pharmacology in ischemic stroke. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 7129-7136.	7.1	132
9	Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke. <i>Journal of Clinical Investigation</i> , 2019, 129, 1772-1778.	8.2	55
10	A disease cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection. <i>Npj Systems Biology and Applications</i> , 2018, 4, 8.	3.0	45
11	European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). <i>Redox Biology</i> , 2017, 13, 94-162.	9.0	242
12	NOX4-dependent neuronal autotoxicity and BBB breakdown explain the superior sensitivity of the brain to ischemic damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 12315-12320.	7.1	112
13	Data supporting the rat brain sample preparation and validation assays for simultaneous determination of 8 neurotransmitters and their metabolites using liquid chromatography-tandem mass spectrometry. <i>Data in Brief</i> , 2016, 7, 714-720.	1.0	12
14	NOS knockout or inhibition but not disrupting PSD-95-NOS interaction protect against ischemic brain damage. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 1508-1512.	4.3	18
15	Simultaneous determination of 8 neurotransmitters and their metabolite levels in rat brain using liquid chromatography in tandem with mass spectrometry: Application to the murine Nrf2 model of depression. <i>Clinica Chimica Acta</i> , 2016, 453, 174-181.	1.1	55
16	Pharmacology and Clinical Drug Candidates in Redox Medicine. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 1113-1129.	5.4	75
17	Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 1171-1185.	5.4	120